Periodic Reporting for period 1 - BLACANDI (BLACANDI can improve life quality and cut cost of diagnosing and managing bladder cancer in half)
Période du rapport: 2015-07-01 au 2015-12-31
The Horizon2020 phase I feasibility study identified no competitors that could match this end-point; however, a number of competing approaches was identified, which will supplement cytology rather than substitute cystoscopy - and as a result increase cost of care.
Implementation into standard of care would require a clinical study of 4000 patients representing with blood in the urine’ which is planned as the phase II of the BLACANDI Horizon2020 project.
The overall objective of the Bladder Cancer Diagnostic “BLACANDI” project (Phase I + II) is to eliminate or dramatically reduce the use of cystoscopy in the diagnosis and follow-up of bladder cancer patients, and thereby reduce the cost of care of bladder cancer.
Bladder cancer is one of the most expensive cancers to manage. Only 1 out of 10 patients presenting with blood in the urine has bladder cancer; however, in the absence of better assays capable of identifying more than 90% of all cancer cases, cystoscopy has remained the standard of care.
In Europe €1.8 billion/year is spend on cytoscopy just for diagnosing the disease. Due to the risk of recurrence all patients undergo routine cystoscopy often several times/year. Managing recurrence is estimated to cost an additional €1.8 billion/year.
Implementing the BLACANDI system instead of cystoscopy could cut the cost of diagnosing and managing bladder cancer in half.